Skip to content

Clinical trials

Phase 2 Respiratory Distress Syndrome trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Respiratory Distress Syndrome Phase: Phase 2 Clear all

144 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20031
20043
20054
20063
20073
20083
20092
20105
20114
20125
20132
20146
20155
20162
20171
20181
20194
202044
202119
20223
20234
20244
20255
20268

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed56
Terminated31
Unknown status20
Withdrawn14
Recruiting11
Active, not recruiting5
Not yet recruiting5
Suspended2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Windtree Therapeutics7
PPD Development, LP4
University of Minnesota4
GlaxoSmithKline3
Belfast Health and Social Care Trust2
Hamilton Health Sciences Corporation2
Implicit Bioscience2
Johns Hopkins University2
Maimónides Biomedical Research Institute of Córdoba2
Massachusetts General Hospital2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Respiratory Distress Syndrome144
COVID-1945
Acute Lung Injury32
Respiratory Insufficiency15
Coronavirus Infections14
Sepsis10
Pneumonia9
Cytokine Release Syndrome8
Severe Acute Respiratory Syndrome8
Lung Injury5

Trials

Showing 76 to 100 of 144. Each trial links to its page on Pharma Observatory.

44 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.